Shi-Yong Sun

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 16

Top Topics

Endoplasmic Reticulum Stress

Small Cell Lung Cancer

Tyrosine Kinase

Epidermal Growth Factor Receptor

Top Venues

Molecular cancer research : MCR

Molecular carcinogenesis

This page only lists publications with an associated author ORCID identifier.

Publications

Zhen Chen, Karin A Vallega, Vijay K Boda, Zihan Quan, Dongsheng Wang, Songqing Fan, Qiming Wang, Suresh S Ramalingam, Wei Li, Shi-Yong Sun
Targeting Transient Receptor Potential Melastatin-2 (TRPM2) Enhances Therapeutic Efficacy of Third Generation EGFR Inhibitors against EGFR Mutant Lung Cancer. Advanced science (Weinheim, Baden-Wurttemberg, Germany) (2024)
Lijun Wang, Huiliang Yang, Changwei Wang, Mingliang Wang, Jiahui Huang, Thedoe Nyunt, Camilo Osorio, Shi-Yong Sun, Maurizio Pacifici, Veronique Lefebvre, Douglas C Moore, Shaomeng Wang, Wentian Yang
SHP2 ablation mitigates osteoarthritic cartilage degeneration by promoting chondrocyte anabolism through SOX9. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 38 (17) (2024)
Zhen Chen, Karin A Vallega, Dongsheng Wang, Zihan Quan, Songqing Fan, Qiming Wang, Ticiana A Leal, Suresh R Ramalingam, Shi-Yong Sun
Inhibition of hTERT/telomerase/telomere mediates therapeutic efficacy of osimertinib in EGFR mutant lung cancer. The Journal of experimental medicine 221 (11) (2024)
Guangzhi Ma, Yunfu Deng, Luxi Qian, Karin A Vallega, Guojing Zhang, Xingming Deng, Taofeek Kunle Owonikoko, Suresh S Ramalingam, Douglas D Fang, Yifan Zhai, Shi-Yong Sun
Overcoming acquired resistance to third-generation EGFR inhibitors by targeting activation of intrinsic apoptotic pathway through Mcl-1 inhibition, Bax activation, or both. Oncogene 41 (12) (2022)
Luxi Qian, Karin A Vallega, Weilong Yao, Dongsheng Wang, Yifan Zhai, Xia He, Shi-Yong Sun
Therapeutic potential of the novel Bcl-2/Bcl-X L dual inhibitor, APG1252, alone or in combination against non-small cell lung cancer. Molecular carcinogenesis 61 (11) (2022)
Yunfu Deng, Guangzhi Ma, Karin A Vallega, Dongsheng Wang, Mingliang Wang, Changwei Wang, Shaomeng Wang, Suresh S Ramalingam, Shi-Yong Sun
Therapeutic efficacy of the novel SHP2 degrader SHP2-D26, alone or in combination, against lung cancer is associated with modulation of p70S6K/S6, Bim and Mcl-1. Cancer gene therapy 29 (11) (2022)
Lei Zhu, Zhen Chen, Hongjing Zang, Songqing Fan, Jiajia Gu, Guojing Zhang, Kevin D-Y Sun, Qiming Wang, Yong He, Taofeek Kunle Owonikoko, Suresh R Ramalingam, Shi-Yong Sun
Targeting c-Myc to Overcome Acquired Resistance of EGFR Mutant NSCLC Cells to the Third-Generation EGFR Tyrosine Kinase Inhibitor, Osimertinib. Cancer research 81 (18) (2021)
Guoqing Qian, Jianping Guo, Karin A Vallega, Changjiang Hu, Zhen Chen, Yunfu Deng, Qiming Wang, Songqing Fan, Suresh R Ramalingam, Taofeek Kunle Owonikoko, Wenyi Wei, Shi-Yong Sun
Membrane-Associated RING-CH 8 Functions as a Novel PD-L1 E3 Ligase to Mediate PD-L1 Degradation Induced by EGFR Inhibitors. Molecular cancer research : MCR 19 (10) (2021)
Danlei Yu, Wen Zhao, Karin A Vallega, Shi-Yong Sun
Managing Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors Through Co-Targeting MEK/ERK Signaling. Lung Cancer (Auckland, N.Z.) 12 (2021)
You-Take Oh, Shi-Yong Sun
Regulation of Cancer Metastasis by TRAIL/Death Receptor Signaling. Biomolecules 11 (4) (2021)
Zhen Chen, Danlei Yu, Taofeek Kunle Owonikoko, Suresh S Ramalingam, Shi-Yong Sun
Induction of SREBP1 degradation coupled with suppression of SREBP1-mediated lipogenesis impacts the response of EGFR mutant NSCLC cells to osimertinib. Oncogene 40 (49) (2021)
Liqun Zhao, Lei Zhu, You-Take Oh, Guoqing Qian, Zhen Chen, Shi-Yong Sun
Rictor, an essential component of mTOR complex 2, undergoes caspase-mediated cleavage during apoptosis induced by multiple stimuli. Apoptosis : an international journal on programmed cell death 26 (5-6) (2021)
Hongjing Zang, Guoqing Qian, Jack Arbiser, Taofeek K Owonikoko, Suresh S Ramalingam, Songqing Fan, Shi-Yong Sun
Overcoming acquired resistance of EGFR-mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol. Molecular oncology 14 (4) (2020)
Hongjing Zang, Guoqing Qian, Dan Zong, Songqing Fan, Taofeek K Owonikoko, Suresh R Ramalingam, Shi-Yong Sun
Overcoming acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib by combining osimertinib with the histone deacetylase inhibitor panobinostat (LBH589). Cancer 126 (9) (2020)
Jiajia Gu, Weilong Yao, Puyu Shi, Guojing Zhang, Taofeek K Owonikoko, Suresh R Ramalingam, Shi-Yong Sun
MEK or ERK inhibition effectively abrogates emergence of acquired osimertinib resistance in the treatment of epidermal growth factor receptor-mutant lung cancers. Cancer 126 (16) (2020)
Yiting Li, Hongjing Zang, Guoqing Qian, Taofeek K Owonikoko, Suresh R Ramalingam, Shi-Yong Sun
ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib. Cancer 126 (6) (2019)